Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Conditions: Solid Tumor, Adult; Colorectal Cancer; Pancreatic Cancer; Malignant Melanoma; Ras (Kras or Nras) Gene Mutation; BRAF Gene Mutation; CRAF Gene Mutation; Non-Small Cell Lung Carcinoma; Thyroid Carcinoma; Gliomas, Malignant
Interventions: Drug: IK-595
Sponsors: Ikena Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 22, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments